Owkin
Maximilien Grandclaudon is a seasoned expert in preclinical and translational therapeutic research, currently serving as Director of Preclinical & Translational Therapeutic Research at Owkin since August 2023. Prior to this role, Maximilien held positions including Principal Scientist - In-licensing at AQEMIA, and Senior Scientist - Team leader at Generate Biomedicines, where responsibilities included leading optimization efforts in drug development. Earlier experience encompasses significant contributions as a Postdoctoral Researcher at prestigious institutions, such as Dana-Farber Cancer Institute, focusing on novel immune-colorectal organoid models, and Servier, where Maximilien developed preclinical models for evaluating immune checkpoint therapies. Academic qualifications include a Research Doctorate in Immunology from Université Paris-Saclay and a Master 2 in Immunology from Pierre and Marie Curie University.
This person is not in any teams
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.